Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Oxurion NV    OXUR   BE0003846632

OXURION NV

(OXUR)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 09/22 11:30:00 am
2.458 EUR   +0.33%
09/18OXURION : Business Update, H1 2020
AQ
09/17OXURION : Business Update - H1 2020
PU
09/17OXURION : Business Update - H1 2020
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
09/16/2020 09/17/2020 09/18/2020 09/21/2020 09/22/2020 Date
2.6(c) 2.53(c) 2.565(c) 2.45(c) 2.49(c) Last
16 055 21 278 40 093 39 995 9 968 Volume
+1.36% -2.69% +1.38% -4.48% +1.63% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 -36,2 M -42,6 M -42,6 M
Net Debt 2020 - - -
P/E ratio 2020 -2,66x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -56,6 M -66,6 M -66,6 M
Net Debt 2021 - - -
P/E ratio 2021 -2,27x
Yield 2021 -
Capitalization 93,8 M 110 M 110 M
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 77
Free-Float 79,5%
More Financials
Company
Oxurion NV specializes in the research and development of bio-therapeutic products for treating cardiovascular diseases, ophthalmic disorders, and cancers. Net sales break down by source of income as follows: - sales of products (96.8%); - royalties (3.2%). 
More about the company
All news about OXURION NV
09/18OXURION : Business Update, H1 2020
AQ
09/17OXURION : Business Update - H1 2020
PU
09/17OXURION : Business Update - H1 2020
AQ
09/15Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment C..
AQ
09/14OXURION : Business Update and First Half 2020 Financial Results to be announced ..
AQ
09/14OXURION : to Present at H.C. Wainwright & Co 22nd Annual Global Investment Confe..
PU
09/14OXURION : to Present at H.C. Wainwright & Co 22nd Annual Global Investment Confe..
AQ
09/11OXURION : Business Update and First Half 2020 Financial Results to be announced ..
PU
09/11OXURION : Business Update and First Half 2020 Financial Results to be announced ..
AQ
09/02Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 fo..
AQ
09/02BICYCLE THERAPEUTICS : Announces First Patient Dosed in Oxurion's Phase II Trial..
AQ
08/07OXURION NV : Proxy Statments
CO
05/07OXURION NV : 1st quarter results
CO
04/03OXURION NV : Ordinary general shareholder meeting
CO
03/30OXURION : Investigational Drug Vericiguat Significantly Reduced the Risk of the ..
AQ
More news
News in other languages on OXURION NV
01/07OXURION NV : flambe sur des données précoces mais positives sur THR-687
2019OXURION : KBC repasse acheteur
2019OXURION NV : Veröffentlichung des Jahresergebnisses
2019OXURION NV : publication des résultats annuels
2018OXURION NV : Veröffentlichung des Quartalsergebnisses
More news
Chart OXURION NV
Duration : Period :
Oxurion NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION NV
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 7,50 €
Last Close Price 2,45 €
Spread / Highest target 390%
Spread / Average Target 206%
Spread / Lowest Target 22,4%
EPS Revisions
Managers
NameTitle
Patrik de Haes Chief Executive Officer & Executive Director
Thomas Moragne Clay Independent Non-Executive Chairman
Dominique Vanfleteren Chief Financial Officer
Jean Feyen Chief Scientific Officer
Grace Chang Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXURION NV-16.95%110
LONZA GROUP62.00%46 758
CELLTRION, INC.53.87%33 531
SEATTLE GENETICS, INC.56.51%31 483
IQVIA HOLDINGS INC.-0.28%30 052
MODERNA, INC.254.09%27 570